With drug developers and manufacturers facing closer scrutiny on product quality than ever before, it's time to make the most of evolving process analytical technology (PAT) to design robust and cost-effective control strategies to understand more about your biopharmaceutical products.

Recent blockbusters like GLP-1 peptides have sparked unprecedented investment into advanced manufacturing strategies, such as Novo Nordisk's recent $11B acquisition to expand manufacturing capacity. The maturity of PAT tools and the development of sophisticated software and chemometrics now provide the perfect opportunity to revolutionize traditional quality and analytical approaches, achieving the digital manufacturing maturity necessary for the future.

Join over 100 leading PAT scientists, engineers, process development, CMC, MSAT and quality experts at the 3rd Annual PAT and Real Time Quality Summit. Explore cutting-edge data-driven case studies, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve, exceeding stakeholder expectations for faster time to market, and unlocking significant ROI through transformative PAT and real-time quality control.

Don't miss your chance to connect groundbreaking technologies with real-world manufacturing investment decisions. This is the only PAT conference designed exclusively for the pharmaceutical and biopharmaceutical community, where insights turn into action.

URLs:

Brochure: https://go.evvnt.com/2622209-0?pid=91 

Tickets: https://go.evvnt.com/2622209-2?pid=91 

Prices:

Conference+ 2 Workshops - Vendor: USD 5097.00,

Conference+ 1 Workshop - Vendor: USD 4398.00,

Conference Only - Vendor: USD 3699.00,

Conference + 2 Workshops - Discounted: USD 3597.00,

Conference + 1 Workshop - Discounted: USD 3098.00,

Conference Only - Discounted: USD 2599.00,

Conference + 2 Workshops - Industry: USD 4197.00,

Conference + 1 Workshop - Industry: USD 3598.00,

Conference Only - Industry: USD 2999.00

Speakers: Aishwarya Ramanan, Downstream Manufacturing, Science, Technologies Labs and Innovation Scientist PAT, Seagen, Andre Cruz, Senior Manager - Quality Assurance, Services Chemistry and Particle Design, Hovione, Andreas Kunov Kruse, PAT Specialist, Novo Nordisk, Arsh Vyash, Research Data Scientist, Vertex, Darren Whitaker, Automation and Control in Process Chemistry Development, Takeda Pharmaceutical, David Zamora, Global Statistical and PAT Lead, Novartis, Elliott Schmitt, Manufacturing Intelligence, PAT, Novo Nordisk Engineering, Emmanuel Appiah, Director, Analytical Enabling Capabilities - Analytical R AND D, Merck, Guanghui Zhu, Senior Staff Engineer, Takeda Pharmaceutical, John-David McElderry, Associate Director - Analytical Systems, Biogen, Lorenz Liesum, Head of Advanced Analytical Technologies, Roche, Manoharan Ramasamy, Director, Merck, Maria Elipe, Scientific Associate Director, Amgen, Mark Henson, Senior Scientific Fellow, Technology Lifecycle Integration, Takeda Pharmaceutical, Mathieu Bibian, Senior Manager Analytical Research and Development, GlaxoSmithKline, Nidhi Kotecha, Program Director, Gates Biomanufacturing Facility, Nili Persits, Researcher, Massachusetts Institute of Technology, Paul Richardson, Director of Manufacturing Technologies, Pfizer, Rohit Lokhande, Senior Continuous Manufacturing Manager, US Pharmacopeia, Samira Beyramysoltan, Senior Scientist, GlaxoSmithKline, Shashi Prajapati, Associate Director, Vertex, Sankaran Anantharaman, Head of PAT and Innovation Labs - Small Molecule CMC – Biologics AbbVie